The Broyhill Q1 2026 Portfolio Strategy And Positioning

Broyhill said Valvoline was its largest quarterly contributor, citing intact unit economics plus continued gains in unit growth, service mix, and pricing. It also highlighted Honeywell's accelerated aerospace spin-off, which should leave a pure-play automation business worth more than the current conglomerate structure. In healthcare, Broyhill argued IQVIA's clinical trial data and FDA process are structurally resilient and unlikely to be automated away by AI.

Analysis

The common thread is that each business is in a regime where the market is still underpricing operating leverage, but for different reasons. VVV looks like a slow-burn compounder: if service-mix and pricing keep offsetting any commodity/input noise, the real upside is not just earnings resilience but a multiple re-rate as investors stop treating it like a cyclical lube/auto-service name and start valuing the recurring cash flow stream. The second-order winner is any adjacent service network with similar customer retention economics; the loser is the long-only crowd expecting a reversion-to-the-mean margin reset that may never come.

HON is a cleaner catalyst-driven setup because the spin creates a valuation air pocket. Once the aerospace asset is removed, the remaining automation business should screen against pure-play industrial automation peers, and that cohort typically trades at a premium when investors can underwrite software-like recurring revenue and installed-base service. The key risk is timing: if the market remains skeptical about industrial growth for the next 1-2 quarters, the rerating can lag the corporate action, but the separation itself should force index and sector rebalancing flows that support the stock over weeks to months.

IQV is the most interesting intellectually because AI is more likely to compress lower-value analytics spend than to disrupt the regulatory bottleneck. The moat sits in the embedded workflow, proprietary datasets, and coordination layer around trials; that creates a longer-duration defense than most healthcare-tech names have against AI. The contrarian miss is that investors may underestimate how AI can actually improve trial throughput for incumbents, which would expand the pie rather than disintermediate it, making the competitive threat more of a margin-shift risk than a revenue-collapse risk.

Overall, the best setup is to separate secular durability from headline AI fear. The market is already willing to pay for obvious AI beneficiaries, but it is slower to pay for businesses that are protected by process, regulation, and switching costs—exactly where incremental cash flow durability can surprise over the next 12-24 months.

Key Decisions for Investors

• Long IQV vs short a basket of less-protected healthcare data/analytics names for 6-12 months; thesis is that AI shifts spend toward regulated workflow incumbents, not away from them. Risk/reward favors IQV if trial volumes remain stable and AI acts as a productivity tailwind rather than a substitute.
• Buy HON into the spin-off window and hold through the first 1-2 post-separation quarters; expect forced ownership rebalancing and a valuation reset as the remaining automation business is compared against higher-multiple pure plays. Add only if the market sells the event on uncertainty rather than fundamentals.
• Use VVV as a cash-flow compounding long, preferably on any weakness from broader consumer cyclicality fears; the setup works best over 6-12 months if mix and pricing remain intact. Upside comes from multiple expansion, while downside is limited unless volumes roll over sharply.
• Pair long HON / short a broad industrial ETF for the next 3-6 months if you want a cleaner corporate-action catalyst trade; the idiosyncratic rerating from the spin can outpace macro industrial beta. Cover if industrial PMIs inflect materially higher, which would reduce the relative value edge.
• If forced to choose one relative-value expression, prefer long IQV / short high-multiple AI-adjacent healthcare software names over outright long exposure. The market is likely overestimating near-term AI displacement and underestimating the durability of regulated data and trial infrastructure.